Introduction
Retroperitoneal sarcomas (RPS) provide a unique set of challenges for oncologic management. Due to the deep location, presentation often is delayed until the tumors reach a very large size or abut/invade vital abdominal viscera or neurovascular structures. More than 60 % percent of RPS in large institutional series from Memorial Sloan Kettering Cancer Center (MSKCC) and the University of Michigan measured larger than 10 cm, whereas 45 % of patients in a French series had tumors larger than 20 cm [1, 2] . The median tumor size in a Surveillance, Epidemiology, and End Results (SEER) database analysis was 17 cm [3] .
Available data demonstrate a strong relationship between R0 resection and both survival and local recurrence. However, the size of the tumor and its proximity to adjacent organs create technical challenges with regards to achieving a complete resection, and en bloc resection of involved viscera is typically required in approximately three-fourths of patients [1, 2, 4] . It has been noted that, in general, complicated surgeries are best performed in high-volume centers [5, 6•] . This also is important for rare conditions, such as soft-tissue sarcomas (STSs), including RPS [7, 8••] where higher rates of R0 resection are observed in high-volume centers. However, even at high-volume institutions employing aggressive surgical strategies, approximately 12-58 % patients will have R1 resection and up to 20-25 % patients will have R2 resection or unresectable disease [8••, 9-12, 13 ••, 14•, 15] . More recently, there have been several reports in the surgical literature describing improved outcomes with a more aggressive, extended surgical approach to include all adjacent organs, regardless of whether they appear to be involved with tumor or not [8••, 13••] . Although overall survival and local recurrence outcomes appear promising with this extended surgical approach, morbidity is increased and available data are limited by comparison to historical controls and necessary selection bias. This area of research is continuing to evolve.
Even with optimal surgery, rates of local recurrence remain high (25-50 %) [16] . Local-recurrence accounts for nearly 75 % of RPS-related deaths [17] . This establishes the rationale for additional therapy with local efficacy, either pre-or postoperatively. The high incidence of R1 resections suggests a potential role for preoperative therapies to achieve sterilization of microscopic disease and increase R0 resection rates, while also reducing recurrence rates in resectable patients.
Radiotherapy (RT) has a long history in RPS management. Many older series failed to demonstrate an impact on local control or survival with the addition of radiotherapy [18] [19] [20] [21] [22] [23] . This may be due to delivery of subtherapeutic doses as allowed by the available radiotherapy techniques. However, improvements in radiotherapy technology now permit delivery of higher doses while limiting toxicity. Multiple, more contemporary, series have demonstrated a dose-response relationship suggesting improved outcomes with higher doses [1, 2, [24] [25] [26] [27] .
This review provides an update of literature on the role of radiotherapy in the management of RPS and highlights future directions required to improve outcomes in this disease.
Treatment Indications for RT in RPS
& Postoperative radiotherapy (PORT) is typically recommended for close or positive margins and high-grade disease. Additional factors that are considered include tumor size, location, difficulty in surgical excision/intraoperative impression, tolerance to surgery, perfor-mance status, and institutional preference/experience. PORT is usually not offered in the setting of postoperative complications, resulting in poor performance status or delayed recovery, significant postsurgical residual disease, and metastatic disease [2] . & Preoperative radiotherapy (PreRT) is typically employed when tumors are deemed unresectable or marginally resectable. The primary goals of PreRT are to improve resectability and local control. However, PreRT has several other advantages that include decreased intraoperative seeding, superior radiotherapy targeting by natural displacement of adjacent normal tissue, and lower equi-efficacious doses due to better oxygenated tissue [16] . Experience from extremity STS has clearly outlined a role for PreRT that allows delivery of lower total dose while maintaining equivalent local control and survival outcomes at the expense of a higher risk of wound complications [28] . This has significant implications in the management of RPS wherein the deliverable RT dose is highly limited by the presence of adjacent, radiosensitive normal structures. & In light of the advantages of PreRT over PORT, this approach has become increasingly represented in modern series regardless of RPS resectability (Tables 1 and 2) . & Intraoperative RT (IORT) has been conventionally employed by itself or in combination with PORT with the goal of radiotherapy doseescalation. Two primary forms are available: intraoperative electrons (IOERT) and brachytherapy (BRT). Physical displacement of sensitive normal tissue, use of individualized shielding, and the limited penetration of electrons permits the use of a highly biologically effective, single, large fraction of radiation with IOERT. BRT, in contrast, involves placement of interstitial catheters through the surgical bed with intraoperative assistance followed by remote afterloading for treatment using high-dose-rate (HDR) techniques or placement of permanent radiation sources for treatment using low-dose-rate (LDR) techniques. The sharp dose-fall off from BRT forms the basis of using this approach. In either case, IORT is somewhat limited by availability of techniques and experience. There also is concern that intraoperative techniques may raise risks of dose-limiting neuropathy [24] . In the PreRT era, IORT may be particularly attractive when intraoperative evaluation suggests R0 resection is implausible. In such cases, IORT may allow selective radiotherapy boost to the surgical bed without a prolonged delay from completion of PreRT. & Despite improvements in surgical techniques, approximately 20 % of patients remain unresectable at presentation typically due to involvement of neurovascular structures of the retroperitoneum or extensive involvement of the viscera [1, 2] . Definitive RT alone, especially with highly conformal radiotherapy techniques or use of particle beam therapy may be employed in these scenarios, primarily to slow the rate of progression and, potentially, provide symptomatic relief. 
Treatment outcomes: role of RT in RPS
& Historically, reported 5-year overall survival (OS) for patients with RPS has varied over a broad range of 10-65 % [16] . In general, outcomes are worse than those observed in extremity STS. To date, [11] . However, the time to local recurrence was different (PORT: 1 year vs. PreRT: 2.5 years). In a recent update, there continues to be no local control distinction between the two sequences (described later in this review). At the University of Michigan, recurrences were higher in the PORT group compared with the PreRT group (p00.046), although this was not a significant factor on multivariate analysis [26] . Similarly, in series from MD Anderson Cancer Center (MDACC) and the Mayo Clinic, no differences in local control or survival were noted between PreRT versus PORT [27, 33] . & The study populations in these series are extremely heterogenous with respect to presentation, histologies, and radiotherapy sequencing. In addition, due to the retrospective nature, inherent institutional and patient selection biases are unavoidable. Hence, a definite recommendation regarding the role and timing of RT is not possible. In the absence of randomized studies specifically addressing RPS, the role of radiotherapy is largely defined based on treatment principles for extremity STS.
Literature update (2010-current)
In the past 3 years, several institutions have published their experiences in RPS management. Table 2 describes RT use and factors impacting local control and OS in these studies. The reported 5-year disease-free survival (DFS) and OS ranged from 19-52 % and 32-76 %, respectively. There continues to be variations in RT use and sequencing based on institutional preferences. Pertinent features of a few of the larger series are described below: & At the University of California, Los Angeles all patients received neoadjuvant chemotherapy, though timing of RT was variable [34] . The 25 % of patients in whom the surgical specimen demonstrated 995 % necrosis had a significantly better disease-specific survival (DSS) than the remaining 75 % of patients (83 % vs. 34 %, p00.002) and also had significantly better outcomes than that predicted by the MSKCC sarcoma nomogram (39 %, p00.018) [35] . PreRT, however, was not associated with improved DSS. & The University of Florida recently updated their experience with multimodality therapy in RPS [36] . In 58 patients, the 5-year overall survival, cause-specific survival, and local control rates were 49 %, 58 %, and 62 %, respectively. The small size of the postoperatively treated cohort (N016) limited the ability to detect significant efficacy or toxicity differences between PreRT and PORT groups. & Fifty patients with primary RPS treated with curative surgery at Centre Alexis Vautrin were analyzed; 5-year OS and DFS were 46 % and 19 %, respectively [37] . PORT was associated with longer time to recurrence (27 vs Role of radiotherapy in the era of aggressive surgical resection
As discussed, the benefit of RT with conventional surgical approaches remains ill-evidenced. Controversial, in and of itself, is a role for highly aggressive upfront surgical resection that has been suggested to improve outcomes in recent retrospective analyses. We envision an emerging area of controversy regarding the role of RT in RPS management when such highly aggressive surgical approaches are employed. Early experiences describing the impact of RT in the setting of highly aggressive surgical approaches are described below. & In their experience (N0288) comparing aggressive surgical excision with simple complete resection, the Istituto Nazionale Tumori reported that aggressive resection resulted in a significant reduction in adjusted 5-year local recurrence rate (48 % to 29 %, HR 0.64, p00.02) despite only a modest increase in the rates of R0/R1 resections (87.5 % to 90.8 %) [13] . In the entire population, the use of RT was an independent factor with a favorable impact on OS (p00.008) and recurrence-free survival (RFS) (p0 0.057; Table 1 ). However, between the two groups, the absolute magnitude of OS benefit with RT was smaller with more aggressive surgery, while the benefit in RFS was similar. & The French Association of Surgery reported their multi-institutional experience (N0382 patients) and showed that in the setting of complete compartmental resection (systematic resection of uninvolved contiguous organs to obtain wide margins), RT did not have an impact on RFS or OS ( ) appeared better in the RT group. The overall survival was 76 % at 5 years for the entire population. The authors noted that improved OS could be attributed to more aggressive surgical resection with 98 % having a R0/R1 resection. As surgical approaches to RPS evolve, the interplay between RT and surgical extent for both oncologic outcomes and quality of life will mandate continuous reassessment. . As seen in single-institution studies, older age, male gender, nonliposarcoma histology, higher grade, and incomplete surgery were observed to be associated with poorer outcomes [3] . It is important to note that detailed margin status is unavailable within the SEER database and therefore not included in any of these analyses; thus, it is possible that any benefit of radiation may be masked by this important, unexamined variable. & One registry-based sample used a proprietary cancer registry to examine outcomes in 261 RPS patients with negative or microscopically positive margins (clinical R0 resections) [31••] . Five-year causespecific and local failure-free survival (LFFS) were 73 % and 66 % respectively. On multivariate analysis, use of RT in combination with surgery significantly improved LFFS (hazard ratio00.42; 95 % CI, 0.21-0.86, pG0.05). This improvement was noted mainly for patients undergoing simple resection (88 % vs. 69 %, pG0.05); LFFS was similar, with or without RT, for patients undergoing wide resection (67 % vs. 64 %, p90.05). By examining only patients with clinical R0 resections, this study overcomes some of the limitations associated with SEER database analyses and provides supporting evidence for the use of RT in the management of RPS. However, these data also raise the possibility that RT benefits are reduced with more aggressive surgical resection.
Recent reports from population databases

Modern radiotherapy techniques
The constant evolution of radiotherapy technologies permits new opportunities in RPS management. As noted in the sections above, the major obstacle to the delivery of adjuvant radiotherapy is the dose limitations of surrounding normal tissues. Newer techniques, such as Intensity Modulated Radiotherapy (IMRT), and particle beam therapy, such as proton beam radiotherapy (PBRT) and carbon ion radiotherapy (CIRT), allow more conformal dose distributions to irregularly shaped target volumes and oncologist-directed tailoring of radiation doses. IMRT employs modulated photon beams to achieve better conformality; however, it is limited by the gradual dose fall off of photons (Figure 1) . Nonetheless, IMRT is a major advance beyond conventional three-dimensional conformal radiotherapy (3D-CRT) wherein beam shaping was the only tool available to conform radiation doses. In contrast, particle beam therapies exploit physical and/or radiobiological properties to achieve an improved therapeutic index. PBRT achieves highly conformal dose-distributions as a result of the radically reduced exit dose afforded by the Bragg Peak. In RPS, where target volumes abut multiple critical adjacent viscera, PBRT may have significant dosimetric advantages and allow better normal tissue sparing. At the same time, multiple air-tissue interfaces and the positional variability of mobile bowel loops add to the dosimetric uncertainty in actual dose delivered. Techniques for PBRT are still developing and will hopefully reduce these potential limitations. Carbon ions display similar radical reductions in exit dose due to the Bragg Peak. In addition, due to significantly higher linear energy transfer compared to photons and protons, they have higher radiobiological effectiveness, which may be particularly useful for large, hypoxic tumors.
Intensity modulated radiotherapy (IMRT) experience
& In a small City of Hope experience, 14 patients (42.5 %) were treated with IMRT-based PORT while 19 patients (57.5 %) received conventional RT [41] . The tumor surgical bed clinical target volume (CTV-2) with PTV margins was planned to a total dose of 60-65 Gy depending on degree of resection, while a surrounding larger volume of resection bed plus 5-cm margins modified around natural barriers (CTV-1) was planned to 45 Gy. IORT was used to plan the boost in 20 (61 %) patients. None of the patients planned with IMRT developed grade 3/4 acute GI toxicity, compared with 16 % patients treated with 3D conformal techniques (p0NS). IMRT reduced patient weight loss during treatment (−0.1 % with IMRT vs. −3.5 % for conventional RT, p00.009). Amongst patients with a minimum 15 months follow-up, absolute incidence of late grade 3/4 toxicities also was lower in IMRT treated patients (10 % vs. 27 %, p0NS). & The University of Alabama experience with IMRT and selective integrated boosting is described below [42] .
& At University Hospitals Gasthuisberg, an interesting approach was employed to use IMRT to deliver meaningful radiation dose (50 Gy) only to the surface of contact between the tumor mass and the posterior abdominal wall [43] . This is the highest risk area for relapse, often due to challenges achieving negative surgical margins. No intentional attempt was made to include the entire gross target volume (GTV) in the treatment volume. The abdominal wall posterior to the great vessels and the ipsilateral paravertebral space were included in the CTV, which was expanded by 3 cm to generate a PTV. Of 18 patients treated on the pilot study, 11 % experienced grade 3, acute anorexia during RT and one patient (5.5 %) developed perioperative gastric hemorrhage. Local recurrence was noted in two patients (11 %). Overall, the authors supported this approach to treat RPS preoperatively. In addition to the clinical study, a dosimetric study compared 3DCRT and IMRT plans and demonstrated significantly reduced kidney doses and improved PTV doses when IMRT was employed. The conformity index was significantly better for IMRT and 3DCPT compared with 3DCRT and IMRT was borderline superior to 3DCPT (p00.052). 3DCPT plans delivered the lowest bowel, contralateral kidney, and liver doses. & There is limited experience with heavy ions in the management of RPS. The National Institute of Radiological Sciences in Chiba, reported 24 patients with unresectable RPS who were treated with carbon ion RT (CIRT) to a dose of 52.8 to 73.6 GyE in 16 fractions over 4 weeks [47] . An encouraging 5-year survival of 50 % and local control of 69 % was noted despite unresectable disease. No significant GI toxicities were seen.
Radiotherapy dose response
For extremity STS, doses of 60-66 Gy are recommended to treat the postoperative surgical bed. Preoperatively, however, a dose of 50 Gy appears adequate [28] . There has been some suggestion of a dose-response relationship in RPS. A Figure 1 . A case demonstrating highly conformal radiotherapy dose-distributions achieved with intensity modulated radiotherapy (IMRT) as displayed in axial, sagittal, and coronal images. A 79-year-old woman presented with deep abdominal discomfort and lower limb edema leading to a diagnosis of intermediate grade leiomyosarcoma of the inferior vena cava. After multidisciplinary assessment, preoperative radiotherapy using TomoTherapy-based IMRT was offered. A differential dose of 50 Gy to the surgeon-defined, at-risk margin (red contour), and 45 Gy to the entire GTV plus PTV margin (yellow contour) was delivered sparing contralateral kidney (green contour), bowel/peritoneal cavity (black contour), liver, and spinal cord. Ipsilateral kidney (light blue) was sacrificed as part of the planned surgical resection. 50 Gy, 40 Gy, and 15 Gy isodose lines are shown in green, blue, and pink, respectively. The patient remains disease-and toxicity-free 2.5 years after treatment.
National Cancer Institute, prospective, randomized trial in 35 patients, compared IORT (20 Gy) and low-dose PORT (35-40 Gy) with conventional PORT (50-55 Gy) [24] . Reduced local failures and lower GI toxicities were noted in the IORT arm; however, peripheral neuropathy was more common in the IORT arm. Even in the MGH retrospective experience, there was a trend towards improved local control with addition of IOERT to PreRT (83 % vs. 61 % at 5 years), although this did not reach statistical significance [9] . The IOERT dose in this series was dependent on surgical margins (R0: 10 Gy, R1: 12. Prospective dose-escalation studies & Tzeng and colleagues at the University of Alabama reported outcomes of 16 patients prospectively treated with preoperative, selective dose-escalation to the margin at presumed risk [42] . An IMRTbased, simultaneous integrated boost technique was used to prescribe 57.5 Gy to the margin at risk while delivering 45 Gy to lower risk volumes in 25 fractions. The treatment was well tolerated; only one patient had acute grade 3, GI toxicity. Nearly 90 % patients had complete macroscopic resection, with two patients unable to undergo resection due to detection of peritoneal implants at laparotomy. Only two patients amongst those who had complete macroscopic resection developed recurrent disease, with a 2-year actuarial local control rate of 80 %. A companion treatment planning study to assess dosimetric feasibility of further dose-escalation to the margin at risk suggested the high-risk planning target volume (PTV) could be dose-escalated to 70 Gy without compromising a smallbowel dose limit of V54 GyG20 cc. & At the German Cancer Research Center (DKFZ), Heidelberg, a phase I/ II study is being conducted evaluating preoperative, dose-escalated IMRT (50-56 Gy to GTV plus 1.5-cm expansion to generate an anatomically modified CTV) to be followed by IORT boost (10) (11) (12) 
Radiotherapy volumes and dose constraints
& Optimal radiotherapy volumes for RPS treatment are not well-defined. Generally a policy to include the surgical bed with appropriate margins to cover microscopic disease while avoiding critical structures has been followed for PORT. In the 3D-planning era, PORT is typically targeted to a 3-5-cm expansion on the tumor bed with appropriate anatomic modifications [9, 26, 37, 50] . When planning PreRT, the GTV is expanded using similar margins to generate a PTV [9, 26] . & With increasing use of highly conformal radiotherapy techniques, careful radiation planning, attention to normal tissue tolerances and reproducible positioning of both target and normal tissues are critical. In the University of Alabama study, the high-risk target volume and the contralateral kidney (V23GyG33 %) were given the highest priority followed by spinal cord (DmaxG45 Gy) and then low-risk target volume, liver (whole liverG33 Gy), and small bowel (DmaxG 45 Gy), although the latter had an absolute dose limit of V54GyG 20 cc [42] . In the MGH study, normal tissue dose constraints were cord DmaxG48 Gy, contralateral kidney V20G33 %, liver V25GyG 50 %, and V30 GyG40 %, small-bowel Dmax preferablyG50.4 Gy, although small volumes were allowed to reach 57. 
Importance of multidisciplinary input for RT planning
& Inputs from the operating surgeon and diagnostic radiologists are critical for PreRT planning. With modern techniques that allow tailoring of radiation dose distributions, several surgical factors can guide modification of radiation plans. Diagnostic studies should be employed to assess involvement of adjacent normal viscera. Based on this information, the team should develop an operative plan prior to initiation of radiation. For example, if nephrectomy is anticipated, exquisite attention must be given to ensure adequate contralateral kidney function is present and preserved. If escalated radiation doses are contemplated, high-risk areas for potentially positive margins should be defined in concert with diagnostic radiologists and the operating surgeon. If complex anastomoses are anticipated, radiation doses may be tailored to limit dose to the regions of interest and reduce risk of anastomotic leak. & For patients taken directly for resection, the radiation oncologist should be included in upfront treatment planning. Surgeons may improve PORT planning by placement of surgical clips in areas of suspected positive margins. Moreover, surgeons may perform omentoplasty or placement of tissue expanders to displace bowel and improve normal tissue dosimetry with PORT.
Future trends
For RPS, prospective studies that unequivocally define the optimal extent of surgical resection, establish the need for radiotherapy and clarify the ideal sequencing of radiotherapy are lacking. The American College of Surgeons Oncology Group (ACOSOG) initiated a phase 3 randomized trial that compared preoperative RT and surgery with surgery alone. Unfortunately, the trial had to be closed early due to poor accrual. This question is currently being studied in a randomized, controlled trial through the European Organization for the Research and Treatment of Cancer (EORTC 62092-22092), which, if completed, will significantly advance our approach to RPS. Clearly, one of the key factors in addressing the unanswered questions in RPS management and advancing our approach to this disease will be the support and initiation of additional, tractable clinical trials. Similarly, roles for chemotherapy in RPS management are unclear. It is generally believed that chemotherapy efficacy is more dependent on histology and biological behavior than anatomic location. Thus, results from studies in nonretroperitoneal soft-tissue sarcoma may be applicable. However, an impact of anatomic location on soft-tissue sarcoma chemosensitivity cannot be completely disregarded [51] [52] [53] . Moreover, with the very large tumors characteristic of RPS, issues of bioavailability may require consideration. Finally, the use of systemic therapy as a radiosensitizer must be cautiously approached, because normal tissue constraints in RPS are more pressing than in most other soft-tissue sarcoma sites.
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